Literature DB >> 33755849

Necroptosis and RhoA/ROCK pathways: molecular targets of Nesfatin-1 in cardioprotection against myocardial ischemia/reperfusion injury in a rat model.

Masoomeh Sharifi1,2, Donya Nazarinia3, Fatemeh Ramezani1, Yaser Azizi1,2, Nasim Naderi4, Nahid Aboutaleb5,6.   

Abstract

Nesfatin-1 as a new energy-regulating peptide has been known to display a pivotal role in modulation of cardiovascular functions and protection against ischemia/reperfusion injury. However, the detailed knowledge about molecular mechanisms underlying this protection has not been completely investigated yet. This study was designed to clarify the molecular mechanisms by which nesfatin-1 exert cardioprotection effects against myocardial ischemia-reperfusion (MI/R). Left anterior descending coronary artery (LAD) was ligated for 30 min to create a MI/R model in rats. MI/R rats were treated with three concentrations of nesfatin-1 (10, 15 and 20 µg/kg) then expression of necroptosis and necrosis mediators were measured by western blotting assay. Fibrosis, morphological damages, cardiac function, myocardial injury indictors and oxidative stress factors were evaluated as well. Induction of MI/R model resulted in cardiac dysfunction, oxidative stress, increased activity of RIPK1-RIPK3-MLKL axis and RhoA/ROCK pathway, extension of fibrosis and heart tissue damage. Highest tested concentration of nesfatin-1 markedly improved cardiac function. Moreover, it reduced oxidative stress, collagen deposition, and morphological damages, through inhibiting the expression of necroptosis mediators and also, necrosis including RIPK1, RIPK3, MLKL, ROCK1, and ROCK2 proteins. The lowest and middle tested concentrations of nesfatin-1 failed to exert protective effects against MI/R. These findings have shown that nesfatin-1 can exert cardioprotection against MI/R in a dose dependent manner by suppressing necroptosis via modulation of RIPK1-RIPK3-MLKL axis and RhoA/ROCK/RIP3 signaling pathway.

Entities:  

Keywords:  Myocardial infarction; Necroptosis; Nesfatin-1; RIPK1-RIPK3-MLKL axis

Mesh:

Substances:

Year:  2021        PMID: 33755849     DOI: 10.1007/s11033-021-06289-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  33 in total

Review 1.  Acute hyperglycaemia: a 'new' risk factor during myocardial infarction.

Authors:  Antonio Ceriello
Journal:  Eur Heart J       Date:  2004-11-30       Impact factor: 29.983

Review 2.  Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling.

Authors:  Gerald W Dorn
Journal:  Cardiovasc Res       Date:  2008-09-08       Impact factor: 10.787

3.  Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Left Ventricular Remodeling After Acute Myocardial Infarction by Inhibiting Monocyte-Mediated Inflammation.

Authors:  Yajing Mao; Jun-Ichiro Koga; Masaki Tokutome; Tetsuya Matoba; Gentaro Ikeda; Kaku Nakano; Kensuke Egashira
Journal:  Int Heart J       Date:  2017-07-13       Impact factor: 1.862

4.  Microneedles for painless transdermal immunotherapeutic applications.

Authors:  Hamed Amani; Mohammad-Ali Shahbazi; Carmine D'Amico; Flavia Fontana; Samin Abbaszadeh; Hélder A Santos
Journal:  J Control Release       Date:  2020-12-17       Impact factor: 9.776

5.  Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury.

Authors:  Shizuka Koshinuma; Masami Miyamae; Kazuhiro Kaneda; Junichiro Kotani; Vincent M Figueredo
Journal:  J Anesth       Date:  2013-10-11       Impact factor: 2.078

6.  Fibroblast Growth Factor-1 Released from a Heparin Coacervate Improves Cardiac Function in a Mouse Myocardial Infarction Model.

Authors:  Zhouguang Wang; Daniel W Long; Yan Huang; Sinan Khor; Xiaokun Li; Xiao Jian; Yadong Wang
Journal:  ACS Biomater Sci Eng       Date:  2017-04-05

7.  Coacervate Delivery of Growth Factors Combined with a Degradable Hydrogel Preserves Heart Function after Myocardial Infarction.

Authors:  Noah Ray Johnson; Maritza Kruger; Kyle Peter Goetsch; Peter Zilla; Deon Bezuidenhout; Yadong Wang; Neil Hamer Davies
Journal:  ACS Biomater Sci Eng       Date:  2015-08-10

8.  Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury.

Authors:  Andreas Linkermann; Jan H Bräsen; Nina Himmerkus; Shuya Liu; Tobias B Huber; Ulrich Kunzendorf; Stefan Krautwald
Journal:  Kidney Int       Date:  2012-01-11       Impact factor: 10.612

9.  Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries.

Authors:  Hamed Amani; Rouhollah Habibey; S J Hajmiresmail; Shahrzad Latifi; Hamidreza Pazoki-Toroudi; Omid Akhavan
Journal:  J Mater Chem B       Date:  2017-11-24       Impact factor: 6.331

10.  Lifestyle Indices and Cardiovascular Disease Risk: A Meta-analysis.

Authors:  Janett Barbaresko; Johanna Rienks; Ute Nöthlings
Journal:  Am J Prev Med       Date:  2018-10       Impact factor: 5.043

View more
  5 in total

Review 1.  "Sibling" battle or harmony: crosstalk between nesfatin-1 and ghrelin.

Authors:  Xi Chen; Jing Dong; Qian Jiao; Xixun Du; Mingxia Bi; Hong Jiang
Journal:  Cell Mol Life Sci       Date:  2022-03-03       Impact factor: 9.261

Review 2.  The regulation of necroptosis and perspectives for the development of new drugs preventing ischemic/reperfusion of cardiac injury.

Authors:  Leonid N Maslov; Sergey V Popov; Natalia V Naryzhnaya; Alexandr V Mukhomedzyanov; Boris K Kurbatov; Ivan A Derkachev; Alla A Boshchenko; Igor Khaliulin; N Rajendra Prasad; Nirmal Singh; Alexei Degterev; Evgenia A Tomilova; Ekaterina V Sapozhenkova
Journal:  Apoptosis       Date:  2022-08-20       Impact factor: 5.561

3.  Simvastatin-loaded nano-niosomes efficiently downregulates the MAPK-NF-κB pathway during the acute phase of myocardial ischemia-reperfusion injury.

Authors:  Maryam Naseroleslami; Masoomeh Sharifi; Neda Mousavi Niri; Nahid Aboutaleb
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

Review 4.  Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury.

Authors:  Carlota Fernandez Rico; Karidia Konate; Emilie Josse; Joël Nargeot; Stéphanie Barrère-Lemaire; Prisca Boisguérin
Journal:  Front Cardiovasc Med       Date:  2022-02-17

5.  Therapeutic potentials of cell death inhibitors in rats with cardiac ischaemia/reperfusion injury.

Authors:  Ying Luo; Nattayaporn Apaijai; Suchan Liao; Chayodom Maneechote; Titikorn Chunchai; Busarin Arunsak; Juthipong Benjanuwattra; Panat Yanpiset; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Cell Mol Med       Date:  2022-03-21       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.